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Abstract 
Nimesulide is a non-steroidal anti-inflammatory drug that acts through selective inhibition of 
COX-2 enzyme. Poor bioavailability of this drug may leads to local toxicity at the site of 
aggregation and hinders reaching desired therapeutic effects. This study aimed at formulating 
and optimizing topically applied lotions of nimesulide using an experimental design 
approach, namely response surface methodology. The formulated lotions were evaluated for 
pH, viscosity, spreadability, homogeneity and in vitro permeation studies through rabbit skin 
using Franz diffusion cells. Data were fitted to linear, quadratic and cubic models and best fit 
model was selected to investigate the influence of permeation enhancers, namely propylene 
glycol and polyethylene glycol on percutaneous absorption of nimesulide from lotion 
formulations. The best fit quadratic model explained that the enhancer combination at equal 
levels significantly increased the flux and permeability coefficient. The model was validated 
by comparing the permeation profile of optimized formulations’ predicted and experimental 
response values, thus, endorsing the prognostic ability of response surface methodology. 
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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used drugs for 
symptomatically alleviating pain and swelling associated with conditions such as arthritis, 
toothache, dysmenorrhea and other musculoskeletal disorders. NSAIDs act by inhibiting 
inflammatory mediators, namely cyclo-oxygenase (COX) enzymes, which are responsible for 
producing prostaglandins (1). The COX-1 isoform is implicated in homeostasis while COX-2 
is particularly associated with inflammatory reactions (2, 3). Nimesulide (4-nitro-2-
phenoxymethanesulfonanilide) is the first marketed NSAID that act through selective 
inhibition of COX-2 (1, 4, 5). Structurally, nimesulide contains sulfoanilide moiety which 
makes it a weekly acidic drug (pKa=6.5) as shown in Figure 1.  
Figure 1 
This drug presents a very low aqueous solubility (0.01 mg/mL), an octanol-water partition 
coefficient (logP) of 2.60 and low bioavailability, therefore, it has been classified as Class II 
drug according to Biopharmaceutics Classification System (BCS) (6, 7). Poor bioavailability 
of this drug may leads to local toxicity at the site of aggregation and hinders reaching desired 
therapeutic effects (7). Taking into consideration the physicochemical properties and poor 
bioavailability of nimesulide, it can be a good candidate for transdermal drug delivery as an 
alternative to oral route of its delivery.  
Transdermal drug delivery has gained significant attention in recent years. It provides several 
advantages over oral route including patient compliance, avoidance of gastrointestinal 
untoward effects and maintains a steady state plasma concentration (8). Transdermal drug 
delivery facilitates the passage of therapeutic quantities of drug through the skin into the 
general circulation, thus bypassing the hepatic first pass effect (9). Research has been carried 
out to overcome the barrier properties of the stratum corneum (SC) of the skin using physical 
and chemical methods. The physical enhancement techniques currently in use, for example 
iontophoresis and sonophoresis, require complex equipment (9, 10). Alternatively, chemical 
enhancement techniques involved use of chemical compound known as permeation enhancers 
which temporarily lower the impermeability of SC, thus facilitate the drug to pass through the 
skin. Commonly used permeation enhancers are alcohols with long carbon chains, cyclic 
monoterpenes, surfactants, pyrrolidones, propylene glycol, isopropyl myristate and dimethyl 
sulfoxide (11-13).  
  
In the development of transdermal formulations, it is essential to design an optimized 
formulation that has appropriate percutaneous absorption.  In recent years a computer 
optimization technique based on response surface methodology (RSM) has been widely 
practiced (14-19). The methodology encompasses utilization of polynomial equations and 
mapping of the responses over the experimental domain to quantify the influence of 
formulation variables on the drug permeation and assist predicting the optimal formulation. It 
reduces the number of experimental runs necessary to establish a mathematical trend in the 
experimental design allowing for the determination of the optimum level. Reducing the 
number of experiments by optimizing a formulation during development of a drug delivery 
device may also lead to significant reductions in production costs (20). 
The present study aimed at formulating and optimizing the permeation of nimesulide from its 
topical lotion formulation using experimental design. All the formulated lotions were 
subjected to physical characterization and in vitro permeation across rabbit skin. RSM was 
employed to assess the influence of formulation variables on the percutaneous absorption of 
nimesulide. Data were assessed to predict the optimized formulation to validate the model.  
 
Experimental 
Materials 
Nimesulide 99.9 % purity (Merck, Germany), propylene glycol (Merck, Germany), 
polyethylene glycol (PEG-400) (Fluka, Germany), isopropyl alcohol (IPA) (Merck, 
Germany), methanol-HPLC grade 99% (Merck, Germany), Tween-20 (Merck, Germany), 
potassium di-hydrogen phosphate  (Fluka, Germany), sodium chloride (Merck, Germany), 
potassium chloride (Sigma-Aldrich, UK), di-Sodium hydrogen phosphate (Fluka, Germany), 
vacuum Grease (Dow Corning,  USA), carbopol-940 (Merck, Germany) and sodium 
hydroxide (Shama Laboratory chemical works, Pakistan) were used as received. 
High-performance liquid chromatography (HPLC) analysis 
Quantitative analysis of  nimesulide was performed as described previously (21) using a 
Waters HPLC system (Elstree, UK) equipped with a 600E pump, a 484 UV-visible detector, 
an autosampler and a C18 Nucleosil®  5 µm column of 150 mm length and 4.5 mm internal 
diameter (Alltech Associates, Deerfield IL). The mobile phase consisted of acetonitrile–
methanol–15 mM potassium di-hydrogen phosphate buffer, pH 7.3 (30:5:65 v/v). Mobile 
phase was filtered through 0.45 µm filter and degassed using ultrasonic bath for 30 minutes 
  
prior to use. The flow rate was adjusted to 1 mL/min and UV detector was set at 393nm 
wavelength. The HPLC analysis was performed at ambient temperature.  
Solubility Studies 
The solubility of nimesulide was measured in various solvents: distilled water, phosphate 
buffered saline (PBS; pH 7.2), methanol, mixture of PBS-methanol (1:1 v/v), propylene 
glycol (PG), and polyethylene glycol (PEG-400). An excess quantity of nimesulide was 
stirred with each of the solvent for 48 hours in thermostatic conditions (37± 2ºC). Samples 
withdrawn were filtered through 0.2 µm nylon filter (Fisher Scientific, UK) followed by 
dilution with appropriate solvent. The concentration of nimesulide was then determined in 
triplicate using HPLC.  
 
Preparation of topical formulation 
In order to optimize the formulation and valuation of the influence of formulation variables 
on nimesulide permeation, a central composite design (CCD) with  = 2 was employed as per 
standard protocol. The factors, namely PG (X1) and PEG (X2) studied at 5 levels (-2, -1, 0, 1, 
2) were selected based on the results of preliminary experiments. Preliminary experiments 
were conducted utilising PG and PEG combination at two concentrations, namely 5% and 
40%. It was found that the combination of enhancers could enhance the permeation of 
nimesulide. Therefore, it was decided to optimize lotion formulations within the studied 
range. The central point (0, 0) was studied in quintuplicate. All other formulation and 
processing variables were kept invariant throughout the study as given in Table 1. 
 
Table 1 
 
Nimesulide hydro-alcoholic lotions (100 mL each) were prepared as per the CCD design 
as shown in Table 1. Essentially, 1 g nimesulide was dissolved in 20 mL of mixture of 
PBS-methanol (1:1 v/v) followed by the addition of PG and PEG according to the CCD 
design. It was stirred over a magnetic stirrer for 30 minutes until solution was 
homogenised. Isopropyl alcohol (20 mL) was taken in a separate flask and 0.2 g carbopol-
940 was added to it with constant stirring. To this solution, 4 mL Tween-20 was added and 
it was stirred for another 30 minutes. Both solutions were then mixed over continuous 
stirring and final volume (100 mL) was achieved by adding mixture of PBS and methanol 
  
(1:1 v/v). An enhancer (PG and PEG) free lotion was also prepared as control (LC). 
In vitro characterization 
Each nimesulide containing lotion was subjected to tests in order to determine its pH, 
viscosity, spreadability, and homogeneity.  Each of these studies was conducted in triplicate 
(n=3). 
Lotion pH was measured with a digital pH meter (Mettler & Toledo, Giessen, Germany).  
Viscosity evaluations were conducted at room temperature (25 ± 2°C) using a Model 
RVTDV II Brookfield viscometer (Stoughton, MA).  A C-50 spindle was employed, with a 
rotation rate of 220 rpm.  The gap value was set to 0.3 mm. 
The spreadability of each lotion was determined by the wooden block and glass slide method 
as detailed previously (22).  Essentially, a 5mL volume of lotion was added to a dedicated 
pan and the time taken for a movable upper slide to separate completely from the fixed slides 
was noted.  Spreadability was determined according to the formula: 
t
LMS ×=
           (1) 
Where: 
          S = Spreadability 
         M = Weight/Volumes tide to upper slide 
          L = Length of glass slide 
          t = Time taken to separate the slide completely from each other 
Each formulated lotion was evaluated for homogeneity by naked eye examination. This 
involved a subjective assessment of appearance including the presence of any aggregates. 
Permeation studies 
This study was conducted under the conditions that had been regulated and approved by the 
Animal Ethics Committee of Bahauddin Zakariya University, Pakistan. White New Zealand 
male rabbits weighing between 3-4 kg were used for the preparation of skin. The skin 
samples were excised from the abdomen region. Hairs were clipped short and adhering 
subcutaneous fat was removed carefully from the isolated full thickness skin. The skin was 
cut into samples that were just larger than the surface area of the Franz diffusion cells. To 
  
remove extraneous debris and any leachable enzyme, the dermal side of the skin was kept in 
contact with a normal saline solution for 1 hour prior to start the diffusion experiments.  
Permeation experiments were performed using Franz cells manufactured ‘in house’, 
exhibiting a diffusional area of 0.85cm2 and a receptor cell volume of 4.5 mL. Subsequently, 
the test membrane was inserted as a barrier between the donor and receiver cells. Silicone 
grease was applied in order to create a good seal between the barrier and the two Franz 
compartments.  To start each permeation experiment, 1 mL volume of each lotion 
formulation was deposited in the donor cell while receptor compartment was filled with PBS-
methanol mixture (1:1 v/v). The diffusion cells were placed on a stirring bed (Variomag, US) 
immersed in a water bath at 37 ± 5°C to maintain a temperature of ~32°C at the membrane 
surface.  At scheduled times, a 0.5 mL aliquot of receiver fluid was withdrawn and the 
receiver phase was replenished with 0.5 mL of fresh pre-thermostated PBS-methanol 
mixture.  Withdrawn aliquots were assayed immediately by HPLC for nimesulide 
quantification. Sink conditions existed throughout. Since skin exhibits large sample-to-
sample permeability differences (23), therefore, each experiment consisted of 5 replicate runs 
(n=5).  
Data Analysis 
 
According to Fick’s second law of diffusion, the cumulative amount of drug (Qt) appearing in 
the receptor solution in time t is expressed in Eq. 2: 
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where A, is the effective diffusion area, C0, represents the drug concentration which remains 
constant in the vehicle, D is the diffusion coefficient, L denotes the thickness of the 
membrane and K is the partition coefficient of the drug between membrane and vehicle. At 
steady state, it is expressed in Eq. 3: 

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The steady state flux (J) was calculated from the slope of the linear plot of the cumulative 
amount permeated per unit area as a function of time, in the steady-state region where the 
  
drug would pass by constant rate. The lag time was determined from the x-intercept of the 
slope at the steady state. The flux is expressed in Eq. 4; 
PKCL
KDCJ 00 ==
                      (4)
 
From this relation the permeability coefficient was calculated using Eq. 5;  
0C
JK P =
            (5)
 
The effectiveness of penetration enhancers (enhancement ratio, ER) was calculated from the 
ratio of nimesulide flux in the presence and absence of enhancers.  
 
The analysis of responses, namely lag time (tlag) and permeability coefficient (KP) were 
performed using Minitab statistical software version 16. Linear, quadratic and cubic 
mathematical models were employed. The best fit model was selected based on the 
comparison of several parameters including the multiple correlation coefficients (R2), 
adjusted multiple correlation coefficients (adjusted R2), predicted residual sum of square 
(PRESS), and the lack of fit (p-value). Experimental design resulted in a quadratic 
polynomial equation which is expressed in Eq.6: 
Y
 
=0+ 1X1+ 2X2+ 12X1X2 – 12X12–  22X22                  (6) 
where Y is the dependent variable (response), 0 is a constant representing the mean of the 
dependent variable obtained in each experiment; X1 and X2  are the independent variables; 
X1X2  are the interaction terms; X12 and X22  are the quadratic term and 1, 2…are the 
coefficients. This expression gives an insight into the effect of the different independent 
variables. A positive sign of coefficient indicates a synergistic effect whereas a negative term 
indicates an antagonistic effect upon the response. Large coefficient means the causal factor 
has potent influence on the response. Afterwards contour and 3D-surface plots visualizing the 
simultaneous effect of the causal factors on the response were established (24). 
The optimization and validation of experimental domain was performed by predicting 
optimum formulation using numerical optimizing provision of the Minitab software. The 
experimental response values and model predicted response values were compared and 
percentage predicted error was calculated. One-way ANOVA was applied to estimate the 
significance of the model (p < 0.05). All measured data are expressed as mean ± standard 
deviation (S.D.). Each measurement was executed in 5 replicates (n= 5). 
 
  
Results and discussion 
Solubility data 
Table 2 illustrates the solubility of nimesulide in each of the studied solvents: distilled water, 
PBS, methanol, PBS-methanol mixture (1:1 % v/v), PG and PEG-400.  Nimesulide is 
sparingly soluble in water (25, 26), for that reason, it was expected that solubility of 
nimesulide in water would be least as confirmed by the solubility studies. Solubility 
enhancement factor was calculated from the ratio of nimesulide solubility in water and 
different solvents. A 3.7-fold higher solubility was achieved in PBS (pH 7.2) which reflects 
the fact that the ionic form of nimesulide is more soluble than its neutral form. Solubility of 
nimesulide in PBS-methanol mixture (1:1 v/v) was 122-fold higher which might be due to the 
solvent polarity difference between two different solvent systems, namely water and PBS-
methanol mixture. Maximum solubility of nimesulide was observed in PEG which was 6864-
fold higher than that in water.  
 
Table 2 
 
In vitro characterization data 
In vitro characterization includes pH, viscosity, spreadability and homogeneity. All the 
formulated lotions were appeared as clear, colourless and aggregate free homogeneous 
solutions upon preparation. All the lotions exhibited a pH value from 5.2  5.4 with no 
significant differences existing between each formulation (data not shown).  However, 
variation in lotion viscosities with respect to PG and PEG content were observed among 
formulations. PEG has higher viscosity then PG, therefore, L3 and L9 showed highest 
viscosities owing to higher PEG levels in the formulations. It can be seen that the viscosities 
of all the enhancer containing lotions were significantly different (p < 0.05) form that of the 
control as confirmed by ANOVA (Table 3).  Furthermore, spreadability data were inversely 
related to the viscosity of each of the nimesulide containing lotion formulation. With 
increasing viscosity, spreadability was decreased as shown in the Table 3. Statistical analysis 
showed significant difference (p < 0.05) between the formulations that were based on axial 
and central points of the CCD. 
In vitro nimesulide permeation through rabbit skin 
The in vitro permeation of nimesulide from its lotion formulation was studied using modified 
Franz cells across rabbit skin. Figure 2 illustrates the cumulative amount of drug permeated 
as a function of time from lotion formulations as per CCD. It can be seen from the Figure 2 
  
that highest permeation was achieved for L3 that contains equal amount of PG and PEG at 
high level. The steady state flux was calculated by a linear regression between cumulative 
amount permeated and time. The lag time (tlag), which is directly related to the drug 
diffusivity, was calculated from the x-intercept of the cumulative amount of drug permeated 
as a function of time. The permeation parameters are listed in Table 3. The tlag values for 
lotion formulations were ranged from 40.9 ± 2.45 min to 109.9 ± 11.8 min. The steady state 
flux (J) ranged from 118.6 ± 2.80 to 180.5 ± 15.9, permeability coefficient (KP) ranged from 
0.060 ± 0.001 to 0.091 ± 0.008, and enhancement ratio (ER) ranged from 2.22 to 3.39 for 
lotion formulations, which indicated that the permeation of nimesulide from its lotion 
formulation was significantly influenced by the proportion of the formulation variables, 
namely PG and PEG. Moreover, lag time, flux and permeability coefficient values for 
enhancer containing lotions were significantly different (P < 0.05) from that of the control 
(LC). 
There are various mechanisms associated with the permeation enhancement of drug by a 
permeation enhancer. They can increase the thermodynamic activity, they can increase 
skin/vehicle partition coefficient, they can increase the solubilizing power of the skin to the 
drug, or they can reversibly reduce the impermeability of skin (27). PG and PEG which are 
commonly used solvents in the pharmaceutical industries were employed in this study as 
permeation enhancers. Previous studies have postulated that PG may carry the drug through 
the barrier layer (28, 29) while other studies describe that PG as a hydrophilic material enters 
the keratin in the corneocyte but does not alter the lipid fluidity in hydrated tissue (30). More 
recently, it has been suggested that PG as a hydrophilic material with two hydroxyl group 
could replace water at the binding sites in the polar head group region and may act in a 
similar way to water (31). Kaushik and co-workers have reported that PEG has a retarding 
effect on permeation of diethylmtoluamide (mosquito repellent) through an anonymous 
mechanism compared to the several other permeation enhancers used in the study (32). As far 
as we could ascertain, there is no published report describing the effect of PG and PEG 
combination on percutaneous absorption of nimesulide. 
 
Figure 2 
 
Table 3 
 
  
The influence of PG and PEG on the permeation of nimesulide from its lotion formulations 
was quantified by analysing the responses (tlag, KP) using RSM. The estimation of 
quantitative effects of the factor combination and their levels on responses was carried out by 
fitting data to linear, quadratic and cubic models. The best fit model was quadratic which 
could be represented as: 
2
2
2
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The significance of formulation variables on nimesulide permeation was evaluated through 
multiple linear regression analysis using Minitab statistical software version 16. The 
comparative values of R2, adjusted R2, PRESS, lack of fit (p-value) are summarized in Table 
4.  
 
RSM data analysis 
Analysis of RSM data revealed a significant model probability at p-value less than 0.05 and 
insignificant lack of fit at p-value greater than 0.05. This implies that the resultant could 
describe the relationship between factors and the responses. The main effects of X1 and X2 
show the average result of changing one variable at a time from its low to higher level while 
interaction effects of X1X2, X12 and X22 represent the results when both factors were altered 
simultaneously. It was observed that responses were considerably influenced by the main 
effect and the interaction of the factors. More interestingly, interaction of factors (X1X2) 
influenced tlag, KP and ER relatively higher than the main effects indicating the PG and PEG 
combination was more suitable in enhancing permeation of nimesulide. The negative 
coefficients of X12 and X22 imply an unfavourable effect of the factors on the permeation of 
nimesulide. The R2 values for Eq. 7 and 8 were found to be 0.583 and 0.776, respectively, 
indicating a reasonable correlation coefficient of the fitted model. The lag time values (Table 
3) revealed significant difference between the formulations based on axial points of the CCD. 
The lag time is dependent on the rate at which drug diffuses through the skin, thus a higher 
drug diffusivity leads to reduction in lag time (29). The longest lag times were obtained for 
the formulations carrying medium or high levels of PG. This may be explained on the basis 
that the enhancing effect of PG is exerted by enhancing the drug partitioning into the stratum 
corneum. To do this, PG has to partition into the SC where it accumulates into the 
intercellular and protein regions of SC, thus changing its solubilizing power with subsequent 
  
increased drug partitioning into the SC (30). The flux values for L1, L5, L6, L8 and L12 were 
found to be similar (Table 3) as these lotion formulations were based on central points of the 
CCD and have similar levels of PG and PEG. It should be noted that lotion formulation 
having equal amount of PG and PEG (L3, formulations based on central points and L10) 
showed a gradual increase in the permeation profile with respect to factor level with L3 
showing the highest flux and permeability coefficient as given in Table 3. The observed 
increase in the permeation profile of nimesulide, when enhancer combination was used in 
equal volume, could be attributed to the fact that PG dehydrates and desolvate the SC (31) 
and disrupts the lipid-protein complex with subsequent increased solubility of nimesulide in 
this membrane. Additionally, presence of PEG also contributed to increase in the solubility of 
nimesulide and may lose its retarding ability in the presence of PG which has disrupted the 
lipid-protein complex in the stratum corneum (32). The retarding effect of PEG is owing to 
its inability to hydrate the SC or its relative osmotic effect which tends to dehydrate the SC 
(33). Since PG tends to disturb the lipid-protein complex in the SC, it was assumed that PEG 
may not act as permeation retardant when SC is disrupted by co-enhancer. This resulted in an 
increased amount of solubilized nimesulide in the SC that creates a concentration gradient 
which facilitated the drug to permeate through the SC.  
This was further analysed by constructing contour and 3-D surface plots (Figures 3 and 4) 
which are useful in visual explanation of the effect of factors on responses. From Figure 3a & 
b, it can be seen that lag time was increased with increasing the concentration of PG in the 
formulations while reverse was true for PEG. The significant decrease in lag time (40.9 ± 
2.45 min for L3) was observed when high levels of PG and PEG were used. Figure 4a & b 
revealed that increasing level of PG in the formulation has positive effect on the KP while 
PEG levels did not show any considerable effect, in fact a negative influence can be observed 
based on regression analysis. However, a gradual increase in the permeation rate of 
nimesulide was observed with increasing levels of PG and PEG combination in the 
formulations. 
 
Validation of RSM 
In order to validate the model described here, an optimized formulation was predicted from 
RSM data using numerical optimization provision of software. This was achieved by 
selecting criteria of attaining minimum value of tlag and maximum value of KP and ER by 
applying constraints on Y1 (25 Y1 60) and Y2 (0.0006  Y1  0.001). This resulted in a 
  
formulation having maximum level of PG (35% w/v) and PEG (35% w/v). Nimesulide lotion 
formulation was fabricated using the predicted values of enhancers and this was subjected to 
in vitro permeation through rabbit skin using Franz diffusion cells. The resultant tlag and KP 
values were 34.6 ± 1.74 (min) and 10.01×10-4 (cm/min), respectively. Predicted responses of 
optimized formulation were 31.2 (min) and 10.24×10-4 (cm/min) for tlag, KP, respectively. 
The percentage predicted error was less than 10% indicating that the experimental and 
predicted values were in good agreement (p < 0.05) with each other, thus validating the 
usefulness and predictive ability of RSM.  
Conclusion 
The present study highlighted the prognostic ability of RSM in optimizing lotion 
formulations of nimesulide and proved to be a useful statistical tool to study the impact of 
variables on responses. The findings of this study suggests that the lotion formulation 
variables have significantly influenced the permeation rate of nimesulide and demonstrated 
that combination of PG and PEG at equal level resulted in higher permeability of nimesulide. 
It is difficult to conclude that if these findings are true with other drugs but it is envisaged 
that the enhancer combination used in this study could produce similar results for other model 
drugs. Future work would be analyzing the optimized formulation in in vivo conditions.   
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Table 1 
 
Lotion 
Formulation 
(L) 
X1 : PG 
 
X2 : PEG 
 
Nimesulide 
% w/v 
Carbopol-940 
% w/v 
Isopropyl 
alcohol 
% w/v 
Tween-20 
% w/v 
L1 0 0 1 0.2 20 4  
L2 0 -2 1 0.2 20 4  
L3 1 1 1 0.2 20 4  
L4 -1 1 1 0.2 20 4  
L5 0 0 1 0.2 20 4  
L6 0 0 1 0.2 20 4  
L7 1 -1 1 0.2 20 4  
L8 0 0 1 0.2 20 4  
L9 0 2 1 0.2 20 4  
L10 -1 -1 1 0.2 20 4  
L11 2 0 1 0.2 20 4  
L12 0 0 1 0.2 20 4  
L13 -2 0 1 0.2 20 4  
Factors Levels used, actual (coded) 
Very low (-2) Low (-1) Medium (0) High (1) Very high (2) 
X1 = PG %w/v 7 14 21 28 35 
X2 = PEG %w/v 7 14 21 28 35 
Response Variables      
Y1: Lag time (tlag) 
Y2: Permeability coefficient (Kp)     
  
  
Table 2 
 
Solvents Solubility (mg/mL) Enhancement factor 
Water 0.009 ± 0.001 - 
PBS 0.033 ± 0.004 3.7 
Methanol 4.950 ± 0.600 550 
PBS + methanol (1:1 v/v) 1.100 ± 0.100 122 
PG 1.715 ± 0.090 190.5 
PEG 400 61.78 ± 3.140 6864 
 
  
  
Table 3 
 
Formulations Viscosity (dynes.s/cm2) 
Spreadability 
(mg.cm/s) 
tlag 
(min) 
J 
(µg/cm2/min) 
KP  
(cm/min) ×10-4 ER 
L1 98 × 10-2 3.71 ± 0.41 93.7 ± 13.6 153.9 ± 5.96 7.7 ± 0.3 2.89 
L2 91 × 10-2 4.72 ± 0.11 62.3 ± 16.7 133.5 ± 2.74 6.7 ± 0.2 2.51 
L3 101 × 10
-2
 3.35 ± 0.39 40.9 ± 2.45 180.5 ± 15.9 9.1 ± 0.8 3.39 
L4 99 × 10-2 3.48 ± 0.14 109.9 ± 11.8 118.6 ± 2.80 6.0 ± 0.1 2.22 
L5 98 × 10-2 3.73 ± 0.92 93.4 ± 13.1 158.4 ± 5.16 7.7 ± 0.3 2.97 
L6 98 × 10-2 3.63 ± 0.67 94.0 ± 12.5 154.2 ± 5.08 7.7 ± 0.3 2.89 
L7 92 × 10-2 4.69 ± 0.78 67.8 ± 9.69 149.5 ± 1.14 7.5 ± 0.1 2.81 
L8 98 × 10-2 3.75 ± 0.52 99.9 ± 18.6 151.7 ± 5.66 7.6 ± 0.3 2.85 
L9 109 × 10-2 3.01 ± 0.21 65.0 ± 18.5 145.7 ± 2.20 7.3 ± 0.1 2.73 
L10 93 × 10-2 4.65 ± 0.13 85.2 ± 15.9 143.3 ± 1.30 7.2 ± 0.1 2.69 
L11 96 × 10-2 3.84 ± 0.09 97.6 ± 9.19  144.1 ± 3.27 7.3 ± 0.2 2.70 
L12 98 × 10-2 3.76 ± 0.32 98.2 ± 8.44 150.2 ± 5.83 7.5 ± 0.4 2.82 
L13 95 × 10-2 3.91 ± 0.49 88.5 ± 7.45 133.7 ± 11.8 6.7 ± 0.6 2.51 
LC 48 × 10-2 4.87 ± 0.92 110.2 ± 11.1 53.3 ± 0.73 2.7 ± 0.1 - 
 
  
  
Table 4 
 
 Coefficient Estimate 
Regression Coefficient tlag KP 
0 92.7 7.68 
0.38 
0.13 
0.70 
-0.15 
-0.16 
0.031 
0.776 
0.616 
13.74 
56.66 
0.913 
1(X1) PG -5.68 
2 (X2) PEG 0.27 
12(X1X2)  -12.9 
1
2 (X12)  -0.88 
2
2 (X22)  -8.2 
Model (p value)   0.000 
R2 0.583 
Adjusted R2  0.485 
PRESS 17915 
F-value  69.23 
Lack of fit (p value)  0.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1 
 
 
  
  
Figure 2 
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Figure 3 
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Figure 4 
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Tables Legend 
Table 1: Factors in Central Composite Design (CCD) for nimesulide formulations 
Table 2: Solubility of nimesulide in different solvents (mean ± S.D.; n = 3) 
Table 3: Viscosity, spreadability and permeation profile of the nimesulide containing lotions 
(mean ± S.D.; n = 5) 
 
Table 4: Summarized statistical parameters of each response variable determined by multiple 
regression analysis 
  
  
Figures Legend 
Figure 1: Structure of nimesulide (Courtesy of ACD I-Lab 2.0) 
Figure 2: Cumulative amount of drug permeated from nimesulide containing lotion 
Figure 3: Estimated contour plot  (a) and response surface (b), illustrating the relationship 
between the permeation enhancers and the lag time.  
Figure 4: Estimated contour  plot (a) and response surface (b), illustrating the relationship 
between the permeation enhancers and the permeability coefficient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
